Literature DB >> 21330454

Sarcoidosis-related mortality in the United States from 1988 to 2007.

Jeffrey J Swigris1, Amy L Olson, Tristan J Huie, Evans R Fernandez-Perez, Joshua Solomon, David Sprunger, Kevin K Brown.   

Abstract

RATIONALE: It has been nearly 20 years since sarcoidosis mortality was examined at the population level in the United States.
OBJECTIVES: To examine mortality rates and underlying causes of death among United States decedents with sarcoidosis from 1988-2007.
METHODS: We used data from the National Center for Health Statistics to (1) calculate age-adjusted sarcoidosis-associated mortality rates; (2) examine how those rates differ by age, sex, and race and ethnicity; and (3) determine underlying causes of death among sarcoidosis decedents.
MEASUREMENTS AND MAIN RESULTS: From 1988-2007, there were 46,450,489 deaths in the United States and 23,679 decedents with sarcoidosis mentioned on their death certificates. Over this time, the age-adjusted, sarcoidosis-related mortality rate increased 50.5% in women and 30.1% in men. The greatest absolute increase in death rates was among non-Hispanic black females. Regardless of sex or race, mortality rates climbed most in decedents 55 years or older. The most common cause of death was sarcoidosis itself. Younger sarcoidosis decedents with pulmonary fibrosis were more likely to be black than white, and younger sarcoidosis decedents were more likely than similarly aged decedents in the general population to have a cardiac cause contribute to death.
CONCLUSIONS: From 1988-2007, sarcoidosis-related mortality rates increased significantly, particularly in non-Hispanic black females aged 55 years or older. The underlying cause of death in most patients with sarcoidosis was the disease itself. Among young sarcoidosis decedents, those with pulmonary fibrosis or a cardiac cause contributing to death were more likely to be black than white.

Entities:  

Mesh:

Year:  2011        PMID: 21330454      PMCID: PMC3137141          DOI: 10.1164/rccm.201010-1679OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  22 in total

1.  Epidemiological study on sarcoidosis in Japan. Recent trends in incidence and prevalence rates and changes in epidemiological features.

Authors:  M Yamaguchi; Y Hosoda; R Sasaki; K Aoki
Journal:  Sarcoidosis       Date:  1989-09

2.  Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation.

Authors:  S M Arcasoy; J D Christie; A Pochettino; B R Rosengard; N P Blumenthal; J E Bavaria; R M Kotloff
Journal:  Chest       Date:  2001-09       Impact factor: 9.410

3.  Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients.

Authors:  E Neville; A N Walker; D G James
Journal:  Q J Med       Date:  1983

4.  Clinical characteristics of patients in a case control study of sarcoidosis.

Authors:  R P Baughman; A S Teirstein; M A Judson; M D Rossman; H Yeager; E A Bresnitz; L DePalo; G Hunninghake; M C Iannuzzi; C J Johns; G McLennan; D R Moller; L S Newman; D L Rabin; C Rose; B Rybicki; S E Weinberger; M L Terrin; G L Knatterud; R Cherniak
Journal:  Am J Respir Crit Care Med       Date:  2001-11-15       Impact factor: 21.405

5.  Sarcoidosis: a long-term follow up study.

Authors:  A G Chappell; W Y Cheung; H A Hutchings
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2000-06       Impact factor: 0.670

6.  The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study.

Authors:  A Pietinalho; Y Hiraga; Y Hosoda; A B Löfroos; M Yamaguchi; O Selroos
Journal:  Sarcoidosis       Date:  1995-03

7.  The clinical course and prognosis of patients with severe, moderate or mild sarcoidosis.

Authors:  K Takada; Y Ina; M Noda; T Sato; M Yamamoto; M Morishita
Journal:  J Clin Epidemiol       Date:  1993-04       Impact factor: 6.437

8.  Sarcoidosis: epidemiology and prognosis. A 15-year European study.

Authors:  G Hillerdal; E Nöu; K Osterman; B Schmekel
Journal:  Am Rev Respir Dis       Date:  1984-07

9.  Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations.

Authors:  A Perry; F Vuitch
Journal:  Arch Pathol Lab Med       Date:  1995-02       Impact factor: 5.534

10.  Sarcoidosis mortality in the United States 1979-1991: an analysis of multiple-cause mortality data.

Authors:  N M Gideon; D M Mannino
Journal:  Am J Med       Date:  1996-04       Impact factor: 4.965

View more
  78 in total

1.  The high frequency of healthcare use in patients one year prior to a sarcoidosis diagnosis.

Authors:  Alicia K Gerke; Fan Tang; Jane Pendergast; Joseph E Cavanaugh; Philip M Polgreen
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2014-10-20       Impact factor: 0.670

Review 2.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 3.  Update in diffuse parenchymal lung disease 2011.

Authors:  Tracy R Luckhardt; Joachim Müller-Quernheim; Victor J Thannickal
Journal:  Am J Respir Crit Care Med       Date:  2012-07-01       Impact factor: 21.405

4.  Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping.

Authors:  Elliott D Crouser; Chikako Ono; Tam Tran; Xin He; Subha V Raman
Journal:  Am J Respir Crit Care Med       Date:  2014-01-01       Impact factor: 21.405

Review 5.  Disease Burden and Variability in Sarcoidosis.

Authors:  Alicia K Gerke; Marc A Judson; Yvette C Cozier; Daniel A Culver; Laura L Koth
Journal:  Ann Am Thorac Soc       Date:  2017-12

6.  Reliability of Cardiovascular Risk Calculators to Estimate Accurately the Risk of Cardiovascular Disease in Patients With Sarcoidosis.

Authors:  Patompong Ungprasert; Eric L Matteson; Cynthia S Crowson
Journal:  Am J Cardiol       Date:  2017-06-15       Impact factor: 2.778

7.  Transcriptional survey of alveolar macrophages in a murine model of chronic granulomatous inflammation reveals common themes with human sarcoidosis.

Authors:  Arjun Mohan; Anagha Malur; Matthew McPeek; Barbara P Barna; Lynn M Schnapp; Mary Jane Thomassen; Sina A Gharib
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-12-06       Impact factor: 5.464

8.  Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.

Authors:  W P Drake; B W Richmond; K Oswald-Richter; C Yu; J M Isom; J A Worrell; G R Shipley
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2013-11-25       Impact factor: 0.670

9.  Circulating cytokines in sarcoidosis: phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease.

Authors:  Karen C Patterson; Beverly S Franek; Joachim Müller-Quernheim; Anne I Sperling; Nadera J Sweiss; Timothy B Niewold
Journal:  Cytokine       Date:  2013-02-04       Impact factor: 3.861

10.  A rare cause of severe lactic acidosis.

Authors:  Saad Saeed; Aditya Kuravi; Matt Rowley; Marwa Saeed
Journal:  BMJ Case Rep       Date:  2015-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.